Aktis Oncology
NASDAQ: AKTSBoston, US · Founded 2020 · Delaware corporation · 102 employees on LinkedIn · 19 known investors
Find your way into Aktis Oncology
660 people in our graph share verified history with the Aktis Oncology team — schools, employers, funds. One of them is your warm intro.
Deep Nisharunlockedknows Todd Foley · together at Harvard Business School (overlapped)
×4knows the team · via Massachusetts Institute of Technology
×6knows the team · via Harvard Business School
knows the team · via Arthur D. Little
Aktis Oncology discovers and develops targeted radiopharmaceuticals for treating solid tumors. The company serves oncology patients and healthcare providers in the cancer care sector.
Founders & leadership
Aktis Oncology was founded in 2020 by Todd Foley and Patrick Baeuerle.
TF
PB
SR
Shulamit Ron-BiggerinChief Operating Officer
KD
AC
Akos CzibereinChief Medical Officer
PL
Paul L. FeldmaninChief Scientific OfficerPaul L. Feldman holds a PhD from UC Berkeley and spent 27 years at GlaxoSmithKline as a senior vice president in R&D, contributing to the discovery of five FDA-approved drugs across multiple therapeutic areas including HIV and pain management. He subsequently co-founded Phoundry Pharmaceuticals in 2015 (acquired by Intarcia Therapeutics), led discovery efforts at Intarcia for five years on metabolic disease therapeutics, and joined Aktis Oncology as Chief Scientific Officer in 2020.
TB
Tyler BeneduminChief Technical OfficerTyler Benedum was an early employee at Avid Radiopharmaceuticals, where he contributed to the development and regulatory approval of Amyvid, a radiopharmaceutical for imaging. He oversaw regulatory filings, facility design, and technical strategy during his tenure at Avid before becoming Chief Technical Officer at Aktis Oncology.
Board
HS
ON
AL
MR
KH
Ken HerrmannBoard director
Investors · 19
Andreessen HorowitzMenlo Park · $500K – $50M
EcoR1 CapitalSan Franciscovia Oleg Nodelman · board
MPM BioImpactBoston · $1M – $15M
MRL Ventures FundCambridge · $25M
RA CapitalBoston
TCG CrossoverPalo Alto
Vida VenturesLos Angelesvia Helen S. Kim · board
Cowen Healthcare InvestmentsreportedNew York
Janus Henderson InvestorsreportedLondon
Pappas CapitalreportedResearch Triangle Park · $100K – $6M
RTW Investments L.P.reportedNew York
Also in the syndicate · 8
ArrowMark PartnersBristol Myers SquibbEli LillyMerck & Co.Mirae Asset VentureNovartisOctagon CapitalTimefolio Capital
Funding
SEC filings, press & company announcements$175M disclosed across 1 of 4 rounds · 2021–2026
- Undisclosed amountseries A extensionAug 2022
ArrowMark Partners, Bristol Myers Squibb, Cowen Healthcare Investments, EcoR1 Capital, Mirae Asset Venture, MPM Capital, MRL Ventures Fund, Novartis, Octagon Capital, Pappas Capital, TCG Crossover, Timefolio Capital, Vida Ventures
Source ↗ - Undisclosed amountSeries AMar 2021Source ↗
▶$175MraisedOct 2024 · 39 investors · BiotechnologyRule 506(b)
▶$175MraisedOct 2024 · 39 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Helen S. KimDirector
- Shulamit Ron-BiggerExecutive Officer
- Ken HerrmannDirector
- Lloyd SegalDirector
- Oleg NodelmanDirector
- Andrew LevinDirector
- Matthew RodenExecutive Officer, Director
- Todd FoleyDirector
- Offering amount
- $175M
- Amount sold
- $175M
- First sale
- Sep 2024
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed events$945.4Mvaluation at IPOJan 2026 · $18.00/share · 424B4
filing ↗Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Competitors · 3
by search overlapBioworld25 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Kite Pharma17 shared keywordsKite develops CAR T-cell therapies that engineer a patient's own immune cells to target and destroy cancer cells. The company focuses on cell therapy treatments for cancers such as diffuse large B-cell lymphoma.
Solu16 shared keywordsSolu Therapeutics is a clinical-stage biotech developing a class of antibody therapeutics that link bifunctional small molecules to proprietary effector antibodies (its CyTAC and TicTAC platforms) to reach cell surface targets like GPCRs and ion channels. Its pipeline targets oncology, immunology and inflammation, and pain, with a lead program in Phase 1 trials for chronic myelomonocytic leukemia.
Companies competing with Aktis Oncology for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Aktis Oncology do?
- Aktis Oncology discovers and develops targeted radiopharmaceuticals for treating solid tumors. The company serves oncology patients and healthcare providers in the cancer care sector.
- Who founded Aktis Oncology?
- Aktis Oncology was founded by Todd Foley, Patrick Baeuerle in 2020.
- Who are Aktis Oncology's investors?
- Aktis Oncology's investors include Andreessen Horowitz, EcoR1 Capital, MPM BioImpact, MRL Ventures Fund, RA Capital, TCG Crossover, Vida Ventures, Cowen Healthcare Investments and 3 more.
- How much funding has Aktis Oncology raised?
- Aktis Oncology has disclosed $175M raised across 1 of its 4 known rounds.
- Where is Aktis Oncology headquartered?
- Aktis Oncology is headquartered in Boston, US.